Budgetary Impact of Covering “Me-Too” Drugs from Social Security: Buenos Aires State Case Report

cic.isFulltexttruees
cic.isPeerReviewedtruees
cic.lugarDesarrolloUniversidad Nacional de La Plataes
cic.versioninfo:eu-repo/semantics/acceptedVersiones
dc.date.accessioned2021-02-11T14:36:07Z
dc.date.available2021-02-11T14:36:07Z
dc.identifier.urihttps://digital.cic.gba.gob.ar/handle/11746/10800
dc.titleBudgetary Impact of Covering “Me-Too” Drugs from Social Security: Buenos Aires State Case Reporten
dc.typeArtículoes
dcterms.abstractThe majority of new drugs registered at Health Global Market are not considered real innovations and due to their chemical structure similarity of reference’s group drug, they are known as “me-too”. These “me too” drugs usually has no additional therapeutic benefits but greatly increasing treatment cost. PURPOSE: To demonstrate the economic impact in Social Security budget by covering “me too” medicines. METHODS: An epidemiological-descriptive-analytical study was performed in order to analyze the burden of anti-hypertensive prescription from patients under coverage by Buenos Aires State Social Security (SS). Two types of medicines were compared: “pioneer/classic” or “me-too”. Variables considered were: medicine type, therapeutical group, global costs, burden for SS and for patients. RESULTS: From 185865 patients with hypertension treated; in 121748 of the cases the strategy was monotherapy while 64117 of them received at least two or more medicines. 189714 were reference drugs while 64393 were considered “me-too”. In average, “me-too” drugs were 41.23% more expensive than classical treatment. The percentage covered by SS varies according to the medicines (between 45 to 51%) and patients must complete the amount of money remaining from their pockets. Paradoxically, the percentage covered by SS of some “me-too” were greater than coverage for most classic medications of each group. CONCLUSIONS: By only choosing the drug of reference from each therapeutical group with has proven effectiveness, the Social Security might increase the coverage to 100% of the cost of all anti-hypertensive treatment for all patients; and even that, still saving almost 2 million dollars per yearen
dcterms.creator.authorMarín, Gustavo H.es
dcterms.creator.authorMarín, Lupees
dcterms.creator.authorAgüero, Danieles
dcterms.creator.authorMarin, Ginaes
dcterms.creator.authorPagnotta, Marianaes
dcterms.creator.authorBlanco, Luises
dcterms.extent234-238es
dcterms.identifier.otherdoi:10.22270/jddt.v10i3-s.4087es
dcterms.identifier.urlhttp://jddtonline.info/index.php/jddt/article/view/4087/3175es
dcterms.isPartOf.issuevol. 10, no. 3, suplemento especiales
dcterms.isPartOf.seriesJournal of Drug Delivery and Therapeuticses
dcterms.issued2020-06-15
dcterms.languageIngléses
dcterms.licenseAttribution 4.0 International (BY 4.0)es
dcterms.subjectHealthes
dcterms.subjectPolicieses
dcterms.subjectMedicineses
dcterms.subjectMe tooes
dcterms.subjectEconomical Burdenes
dcterms.subjectCoveragees
dcterms.subjectAnti-hypertensivees
dcterms.subject.materiaCiencias Médicases

Archivos

Bloque original
Mostrando 1 - 1 de 1
Cargando...
Miniatura
Nombre:
Budgetary Impact of Covering.pdf-PDFA.pdf
Tamaño:
678.42 KB
Formato:
Adobe Portable Document Format
Descripción:
Documento completo